Your browser is no longer supported. Please, upgrade your browser.
Settings
LPCN Lipocine Inc. daily Stock Chart
LPCN [NASD]
Lipocine Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own3.00% Shs Outstand24.59M Perf Week28.04%
Market Cap67.38M Forward P/E6.57 EPS next Y0.42 Insider Trans0.00% Shs Float23.59M Perf Month50.55%
Income-12.30M PEG- EPS next Q-0.15 Inst Own11.50% Short Float0.24% Perf Quarter72.33%
Sales0.00M P/S- EPS this Y-40.70% Inst Trans-0.60% Short Ratio0.51 Perf Half Y61.03%
Book/sh0.40 P/B6.85 EPS next Y176.40% ROA-57.30% Target Price5.67 Perf Year95.71%
Cash/sh0.59 P/C4.65 EPS next 5Y- ROE-113.20% 52W Range1.04 - 2.80 Perf YTD110.77%
Dividend- P/FCF- EPS past 5Y17.60% ROI-57.80% 52W High-2.14% Beta0.70
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low163.46% ATR0.15
Employees10 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)88.52 Volatility9.54% 7.24%
OptionableYes Debt/Eq0.88 EPS Q/Q8.90% Profit Margin- Rel Volume2.70 Prev Close2.74
ShortableYes LT Debt/Eq0.55 EarningsAug 06 Payout- Avg Volume113.81K Price2.74
Recom1.70 SMA2032.98% SMA5042.32% SMA20055.72% Volume0 Change0.00%
Jan-12-18Reiterated H.C. Wainwright Buy $10 → $3
Jan-11-18Downgrade Canaccord Genuity Buy → Hold $11 → $2
Dec-08-17Resumed H.C. Wainwright Buy $10
Oct-07-16Initiated H.C. Wainwright Buy $25
Jul-22-15Initiated ROTH Capital Buy $36
Jun-23-15Initiated Canaccord Genuity Buy $15
Aug-13-19 07:47AM  Is Lipocine (NASDAQ:LPCN) Using Too Much Debt? Simply Wall St. +6.84%
Aug-07-19 08:00AM  Lipocine Announces Second Quarter 2019 Financial and Operational Results PR Newswire +5.56%
Jul-30-19 08:00AM  Lipocine to Present at the Canaccord Genuity 39th Annual Growth Conference PR Newswire
Jul-29-19 10:00AM  LPCN: Poster Demonstrates NASH and Free T Link Zacks Small Cap Research
Jul-23-19 08:00AM  Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population PR Newswire
Jul-11-19 08:01AM  What Percentage Of Lipocine Inc. (NASDAQ:LPCN) Shares Do Insiders Own? Simply Wall St. -5.29%
Jun-28-19 02:19PM  18 Stocks Joining The Russell Indices Benzinga
Jun-25-19 08:00AM  Lipocine Set To Join Russell Microcap® Index PR Newswire
Jun-11-19 12:16PM  Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +6.71%
May-28-19 11:45AM  LPCN: Now We Have PDUFA Date; Target To $7 Zacks Small Cap Research
May-14-19 08:00AM  Lipocine Announces TLANDO NDA PDUFA Action Date of November 9, 2019 PR Newswire +7.22%
May-08-19 08:31AM  Lipocine: 1Q Earnings Snapshot Associated Press
08:00AM  Lipocine Announces First Quarter 2019 Financial and Operational Results PR Newswire
Apr-29-19 07:21AM  Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop? Simply Wall St.
Apr-18-19 10:15AM  LPCN: Turning the Tables Zacks Small Cap Research
Apr-03-19 09:34AM  Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy PR Newswire
Mar-28-19 01:15PM  LPCN: ABPM Study Topline Data Zacks Small Cap Research
Mar-27-19 08:00AM  Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy PR Newswire
Mar-26-19 08:00AM  Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers PR Newswire
Mar-21-19 08:00AM  Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference PR Newswire
Mar-14-19 11:00AM  LPCN: NASH Topline Zacks Small Cap Research +7.88%
08:00AM  Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019 PR Newswire
Mar-12-19 09:40AM  Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate Benzinga
08:00AM  Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population PR Newswire
Mar-06-19 08:00AM  Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018 PR Newswire
Feb-26-19 08:04AM  Does Lipocine Inc.s (NASDAQ:LPCN) CEO Pay Reflect Performance? Simply Wall St.
Feb-14-19 07:00AM  Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects PR Newswire
Jan-25-19 02:00PM  LPCN: Soldiering on and Winning Some Battles Zacks Small Cap Research
Jan-24-19 09:30AM  4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19) ACCESSWIRE
08:00AM  Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects PR Newswire
Jan-17-19 10:00AM  Lipocine's NASH Candidate Shows Promise In Liver Fat Study Benzinga +18.24%
09:10AM  Lipocine's stock rockets on premarket leading volume after upbeat liver fat study results MarketWatch
07:00AM  Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results PR Newswire
Jan-14-19 08:00AM  USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus PR Newswire
Dec-31-18 08:00AM  Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO PR Newswire +21.50%
Dec-21-18 08:00AM  Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference PR Newswire
Dec-20-18 08:00AM  Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD PR Newswire
Nov-26-18 10:30AM  LPCN: Tlando Readouts Coming Soon; NDA to Follow Zacks Small Cap Research
Nov-22-18 11:30AM  Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic? Simply Wall St.
Nov-19-18 08:25AM  Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 08:49AM  Lipocine: 3Q Earnings Snapshot Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018 PR Newswire
Nov-05-18 08:00AM  Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH PR Newswire
Nov-01-18 04:00PM  Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO PR Newswire
Oct-29-18 01:15PM  LPCN: Androgen Therapy in NASH: A Comprehensive Approach Zacks Small Cap Research
Oct-11-18 08:00AM  Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018 PR Newswire
Sep-25-18 08:00AM  Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Sep-19-18 08:51AM  Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)? Simply Wall St.
Aug-29-18 10:00AM  LPCN: 2Q:18 Operational and Financial Results Zacks Small Cap Research
Aug-07-18 08:32AM  Lipocine: 2Q Earnings Snapshot Associated Press
07:30AM  Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018 PR Newswire
Aug-02-18 08:00AM  Lipocine to Present at the Canaccord Genuity 38th Annual Growth Conference PR Newswire
Jun-18-18 07:05AM  Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks ACCESSWIRE
Jun-07-18 08:00AM  Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO PR Newswire
May-16-18 08:59PM  Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN) Simply Wall St.
May-14-18 10:35AM  LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response Zacks Small Cap Research +15.45%
May-11-18 07:00AM  Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks ACCESSWIRE
May-09-18 09:45AM  Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks Benzinga -35.96%
08:45AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:09AM  Lipocine shares drop 38% after FDA fails to approve testosterone replacement therapy MarketWatch
06:59AM  Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration PR Newswire
May-08-18 07:55AM  Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure Benzinga +13.37%
May-07-18 08:27AM  Lipocine: 1Q Earnings Snapshot Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018 PR Newswire
Apr-23-18 08:00AM  Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN GlobeNewswire -9.09%
Apr-20-18 07:20AM  Free Research Report as Lipocine Announced FY17 Financial Results ACCESSWIRE
Apr-02-18 10:15AM  LPCN: Coming at the FDA Like a Spider Monkey Zacks Small Cap Research
Mar-21-18 08:00AM  Lipocine to Present at the 17th Annual Needham Healthcare Conference PR Newswire
Mar-14-18 08:00AM  Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference PR Newswire
Mar-12-18 08:00AM  Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017 PR Newswire -6.33%
Mar-06-18 07:55AM  Interested In Lipocine Inc (NASDAQ:LPCN)? Heres What Its Recent Performance Looks Like Simply Wall St.
Mar-05-18 08:00AM  Lipocine to Present at the 30th Annual ROTH Conference PR Newswire
Mar-02-18 10:50PM  LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. LPCN Business Wire +8.28%
Feb-28-18 08:20AM  Todays Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals ACCESSWIRE +25.00%
Feb-27-18 11:45AM  Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating Benzinga +16.03%
Feb-16-18 10:50PM  LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN PR Newswire
08:00AM  Lipocine Announces Settlement of Securities Class Action Lawsuit PR Newswire
Feb-08-18 08:00AM  Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank PR Newswire -6.98%
Feb-07-18 04:01PM  Lipocine to Present at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Feb-02-18 10:50PM  LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. LPCN Business Wire -6.99%
Jan-29-18 05:12PM  Harwood Feffer LLP Announces Investigation of Lipocine Inc. Business Wire +7.63%
Jan-19-18 11:00AM  LPCN: AdCom Votes 6:13 Against Tlando Zacks Small Cap Research
Jan-12-18 05:06PM  LIPOCINE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine, Inc. To Contact The Firm ACCESSWIRE -8.56%
Jan-11-18 02:49PM  Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades Benzinga -45.95%
11:52AM  FDA Advisers Slam Lipocine's Testosterone Pill, Raising Doubts About 'Low T' Drugs Forbes
06:44AM  Whats Next For Lipocine After A Disappointing Panel Review? Market Exclusive
Jan-10-18 05:07PM  Lipocine Inc (LPCN) Fails to Convince FDA Advisory Committee of TLANDOs Merit; Shares Decline Over 50% SmarterAnalyst
04:40PM  Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism PR Newswire
Jan-08-18 11:46AM  The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In Benzinga +12.87%
Jan-04-18 08:00AM  Lipocine Anticipating Results from Two Near Term FDA Dates, PDUFA and BRUDAC ACCESSWIRE
Nov-22-17 01:00PM  LPCN: Third Quarter Operational and Financial Results Zacks Small Cap Research
Nov-17-17 08:00AM  U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged GlobeNewswire -5.71%
Nov-08-17 08:09AM  Lipocine reports 3Q loss Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 GlobeNewswire
Oct-18-17 08:00AM  FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 GlobeNewswire +7.55%
Sep-22-17 01:00PM  LPCN: Advisory Committee Required and USPTO Issues Motion for Tlando Zacks Small Cap Research
Sep-21-17 08:00AM  Lipocine Announces Motions Decision by USPTO in Interference Against Clarus GlobeNewswire
Sep-20-17 08:00AM  Lipocine Announces FDA Advisory Committee Meeting for TLANDO GlobeNewswire
Sep-19-17 03:02PM  Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-05-17 08:00AM  Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.